东诚药业(002675.SZ)：氟[18F]思睿肽注射液完成III期临床试验

Core Viewpoint - Dongcheng Pharmaceutical's subsidiary, Yantai Lannacheng Biotechnology Co., Ltd., is developing a radiopharmaceutical for PET imaging in prostate cancer patients with PSMA-positive lesions [1] Group 1: Product Development - The product under development is Fluorine-18 labeled PSMA-targeted injection, aimed at diagnosing prostate cancer [1] - It is intended for patients who are candidates for initial radical treatment and those suspected of having metastatic lesions [1] - The drug is also applicable for patients with elevated serum PSA levels who are suspected of biochemical recurrence [1]